A Phase I Study of a Novel Tracer for Positron Emission Tomography PET Myocardial Perfusion Imaging MPI

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02720354

Enrollment

Registered

2016-03-25

Start date

2016-05-31

Completion date

2017-05-31

Last updated

2017-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

\[11C\]-dimethyl-diphenyl ammonium (\[11C\]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial Perfusion Imaging

Interventions

OTHER[11C]-DMDPA

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* body mass index (BMI) between 18.0 and 30.0 kg/m2 * good health * written informed consent

Exclusion criteria

* smokers * subject receiving medication * a blood transfusion in the 4 weeks prior to screening * positive alcohol blood test * Subjects who suffer from claustrophobia * Subjects who have had a clinically significant illness * Subjects exposed to radiation within 12 months prior to screening

Design outcomes

Primary

Measure	Time frame
Measurement of absorbed radiation dose for all target organs in megabecquerel (the activity of a quantity of radioactive material in which one nucleus decays per second).	within 80 minutes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026